drug_type
RELEVANT_DRUG
intervention_type
Adoptive cellular immunotherapy (genetically engineered T cells)
drug_description
Autologous T cells genetically modified to express dual CARs targeting CD19 and CD20 with an autocrine p40 cytokine module to enhance activation, expansion, and persistence; administered after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with dual chimeric antigen receptors targeting CD19 and CD20 recognize malignant B cells and, upon antigen engagement, activate and mediate cytolytic killing; an autocrine p40 cytokine module augments activation, expansion, and persistence, with lymphodepletion supporting engraftment.
drug_name
CD19/CD20-CAR.p40-T
nct_id_drug_ref
NCT07097207